Patent ID: 11866789
Assignee: THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A  G | IPC A  C  G

Claim 8:
9. A method of inhibiting cancer cell growth, comprising:
identifying a cholangiocarcinoma cancer cell containing a RBPMS-NRG1 fusion protein transcribed from an inter-chromosomal DNA translocation in chromosome 8 band p12 of the cell, and having a EGF-like domain on the NRG1 portion of the fusion protein, wherein the RBPMS-NRG1 fusion includes exons 1-5 of RBPMS and exons 1 and 2 of NRG1;
contacting the cholangiocarcinoma cancer cell containing the RBPMS-NRG1 fusion protein with a therapeutic agent comprising at least one EGFR inhibitor that is targeted for the EGF-like domain of the NRG1 portion of the RBPMS-NRG1 fusion event.